UNIVERSITY OF TEXAS MEDICAL BRANCH

Amendment of Notification of Use for

Biological Agents in the Core Facilities:

Keck Facility

Optical Microscopy Core (OMC) Facilities

The purpose of this document is to ensure adequate review of occupational safety and health precautions and the procedures for use, handling, storage, and disposal of biohazardous agents. As the Principal Investigator (P.I.) or Supervisor, you should be fully aware of the specific or potential hazards associated with the agents used in your work area.

THIS MAY BECOME A PUBLIC DOCUMENT: DO NOT INSERT PROPRIETARY OR SECURITY SENSITIVE INFORMATION.

Type of Submission: New Renewal

Facility: Keck Facility Optical Microscopy Core (OMC) Facilities

The information provided in this document is accurate to the best of my knowledge. I am familiar with, and agree to abide by the provisions set forth in this plan as approved by the University of Texas Medical Branch Institutional Biosafety Committee, the UTMB Safety Manual, the UTMB Institutional Handbook of Operating Procedures (IHOP), the CDC/NIH Biosafety in Microbiological and Biomedical laboratories, most current edition, and NIH guidelines on recombinant work.

When using recombinant DNA, I agree to comply with the NIH Guidelines for Research Involving Recombinant DNA Molecules.

I accept responsibility for training all laboratory workers involved in the research project described in this "Notification of Use" before commencing work.

P.I. (Signature) Responsible for Research / Title / Extension / Date Submitted
P.I. (Printed Name) / UTMB ID# / Department / Route
BIOLOGICAL SAFETY COMMITTEE USE ONLY
DATE APPROVED DATE FOR RESUBMISSION
Chairman (Signature) Printed Name

Note that approval for the use of these facilities is granted on an experimental base not a time frame.

List the agents to be used:
Reference number and date of approved NOU for use of the listed agents

Use of the Keck Center for Virus Imaging BSL-3 FACILITY in MRB

Procedures concerning the use of the Keck Center for Virus Imaging BSL-3 FACILITY in MRB facility will follow standard SOP for this facility.

1. Please indicate the agent and concentration to be used.
2. Has this project been discussed with both Drs. Weaver and Sherman? / No / Yes
3. Please list any major changes from the Standard Operating Procedure for the Cryo EM facility.


Use of the BSL-2 and BSL-3 Optical Microscopy Core (OMC) Facility

Procedures concerning the use of the Optical Microscopy Core (OMC) facility will follow standard SOPs for this facility, as well as the SOPs for the BSL-3 facility (when applicable).

1. Has this project been discussed with both Drs. Motamadi and Vergara? / No / Yes

2. What biosafety level will this work be conducted?

BSL-2, List building:
BSL-3, List building:
3. Please indicate the agent and the highest concentration to be used.
4. Is there an avirulent surrogate of the agent (e.g., vaccine strain or avirulent mutant) that could be used to determine optimum conditions prior to imaging?
5. Is the agent stable at 4ºC, 25ºC, or -80ºC? / No / Yes
6. List all personnel in your lab who will be working in the Imaging facility, indicate if they have received training from the facility staff to work independently in the facility?
7. Please list any major changes from the Standard Operating Procedure for the Optical Microscopy Core (OMC) facility, if any.
8. Please provide data and/or peer-reviewed scientific information that indicate the susceptibility of the agent to 10% buffered formalin, Cavicide, 10-50% bleach, and formaldehyde gas. Be sure to consider the time of exposure in the susceptibility considerations.
9. What animal model do you plan to use?

3

Revised 01/2015